Skip to main content

Table 3 Analyses of prognostic factors for survival

From: Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination

  OS PFS
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95%CI) P HR (95%CI) P HR (95%CI) P HR (95%CI) P
Sex (female VS male) 0.639 (0.222–1.835) 0.405    1.284 (0.534–3.086) 0.576   
Age (per 1 point increase) 1.027 (0.993–1.063) 0.125    1.001 (0.972–1.030) 0.953   
Age group (≥ 65 VS < 65) 2.467 (1.153–5.279) 0.020 2.545 (1.113–5.823) 0.027 1.507 (0.734–3.094) 0.264   
ECOG PS (per 1 point increase) 1.363 (0.664–2.802) 0.399    1.679 (0.891–3.164) 0.109   
BCLC stage (C VS B) 2.185 (0.829–5.756) 0.114    1.922 (0.843–4.379) 0.120   
Tumor size (per 1 point increase) 1.010 (1.003–1.017) 0.003 1.010 (1.003–1.017) 0.005 1.006 (1.000–1.012) 0.052 - -
Tumor size (≥ 10 cm VS < 10 cm) 2.200 (1.050–4.613) 0.037 - - 1.523 (0.803–2.890) 0.198   
Tumor distribution (multiple VS single) 2.190 (0.663–7.233) 0.199    1.890 (0.668–5.344) 0.230   
Child–Pugh class (B VS A) 1.927 (0.878–4.232) 0.102    1.913 (0.965–3.791) 0.063 - -
Extrahepatic metastases (Yes VS No) 1.638 (0.796–3.367) 0.180    1.412 (0.757–2.636) 0.278   
Macrovascular invasion (Yes VS No) 2.533 (1.151–5.574) 0.021 - - 2.332 (1.174–4.632) 0.016 2.193 (1.083–4.443) 0.029
Liver Cirrhosis (Yes VS No) 0.444 (0.126–1.563) 0.206    0.634 (0.218–1.843) 0.402   
Hepatitis B (Yes VS No) 0.562 (0.210–1.504) 0.251    0.965 (0.372–2.501) 0.942   
Co-treatment time (late combination VS early combination) 0.200 (0.077–0.522) 0.001 0.175 (0.060–0.509) 0.001 0.310 (0.144–0.665) 0.003 0.422 (0.184–0.967) 0.041
AFP (≥ 200 VS < 200) 1.946 (0.892–4.244) 0.094 - - 1.846 (0.937–3.636) 0.076 - -
RBC 0.956 (0.599–1.526) 0.956    0.880 (0.590–1.312) 0.529   
WBC 0.941 (0.769–1.153) 0.559    0.892 (0.740–1.075) 0.229   
Platelet 1.004 (1.000–1.007) 0.065 - - 1.002 (0.999–1.006) 0.169   
Hb 0.993 (0.977–1.011) 0.451    0.990 (0.976–1.005) 0.189   
Neutrophils 1.018 (0.829–1.249) 0.866    0.967 (0.803–1.166) 0.728   
Lymphocyte 0.377 (0.166–0.854) 0.019 - - 0.410 (0.200–0.842) 0.015 - -
NLR 1.074 (0.916–1.259) 0.379    1.078 (0.938–1.240) 0.288   
ALT 1.004 (0.995–1.014) 0.362    1.003 (0.996–1.010) 0.372   
AST 1.004 (0.998–1.009) 0.189    1.003 (0.999–1.008) 0.130   
TBIL 1.006 (0.973–1.040) 0.716    1.002 (0.971–1.034) 0.901   
ALP 1.005 (1.002–1.008) 0.002 - - 1.004 (1.002–1.007) 0.002 1.004 (1.001–1.007) 0.017
TBA 0.994 (0.982–1.007) 0.348    1.000 (0.994–1.006) 0.948   
ALB 0.949 (0.884–1.018) 0.142    0.948 (0.892–1.008) 0.088 - -
  1. ECOG PS Eastern Cooperative Oncology Group Performance Status, BCLC Barcelona Clinic Liver Cancer, RBC red blood cell, Hb Hemoglobin, WBC white blood cell, NLR Neutrophils/ Lymphocyte, ALT Alanine aminotransferase, AST Aspartate aminotransferase, TBIL total bilirubin, ALP alkaline phosphatase, TBA total bile acid, ALB albumin, AFP alpha-fetoprotein
  2. Early combination was defined as treatment with apatinib and camrelizumab after the first or second TACE. Late combination was defined as having had at least three times TACE before receiving treatment with apatinib and camrelizumab